ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study)

He, Meijiao; Yan, Wei; Zhang, Yun; Kong, Yihui; Han, Xuejie; Ren, Jie; Zhao, Zhongyang; Liu, Guangzhong; Shi, Jing*; Li, Yue*哈尔滨医科大学; 1; y
Platelets2022-11-17DOI: 10.1080/09537104.2022.2052036
2被引10阅读
引用收藏
分享

摘要

Increasing clinical trials demonstrated that the discontinuation of aspirin while maintaining a P2Y(12) inhibitor monotherapy could decrease the risk of bleeding without losing the antithrombotic effect. However, no data are available on the platelet reactivity of patients undergoing ticagrelor monotherapy vs. clopidogrel. Therefore, we performed this study to observe the efficacy of ticagrelor monotherapy vs. clopidogrel in Chinese patients with chronic coronary syndrome. This randomized, single-blinded, crossover trial enrolled 50 patients who were administered with ticagrelor (90 mg twice daily for 2 weeks) or clopidogrel (75 mg once daily for 2 weeks). Followed by a 2-week washout period, the two groups of patients underwent a crossover trial. Light transmission aggregometry (LTA) and thromboelastography (TEG) assays were used to test platelet reactivity. The platelet aggregation rate (PAgR) of ADP and AA was significantly lower with ticagrelor than clopidogrel (PAgR of ADP, 27.30% (7.30%-42.635%) vs. 35.55% (12.03%-69.25%), P = .0254; PAgR of AA, 77.80% (21.60%-86.43%) vs. 83.10% (67.13%-87.20%), P = .0400). There was no significant difference in PAgR of collagen and epinephrine between the two groups. The TEG assay showed that ADP and AA, which induced the inhibition of platelet aggregation, were significantly higher in the ticagrelor group than those in the clopidogrel group [ADP%, 69.00% (59.68%-88.95%) vs. 60.55% (35.98%-78.35%), P = .0020; AA%, 53.65% (22.75%-79.28%) vs. 15.15% (5.75%-70.25%), P = .0127]. High on-treatment platelet reactivity (HTPR) on ADP was 2.17% with ticagrelor and 19.57% with clopidogrel. HTPR on AA was 50.00% with ticagrelor and 69.57% with clopidogrel. Ticagrelor and clopidogrel caused the inhibition of ADP and AA-induced platelet aggregation. Moreover, ticagrelor monotherapy had a stronger inhibitory effect than clopidogrel monotherapy (except on collagen and epinephrine).

学科与关键词

关键词
Chronic coronary syndromeclopidogrelplatelet aggregationticagrelor
相关
加载中…
  • Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention in patients with coronary artery disease: a meta-analysis
    Liu, Di; Xu, Wei Pan; Xu, Hang; Zhao, Lin*; Jin, Dao Qun*Frontiers in Cardiovascular Medicine, 2023, 10: 1265983.
  • Ticagrelor versus clopidogrel in reducing inflammatory cell infiltration of thrombus aspirated in patients with ST-elevation myocardial infarction
    Shen, Jing; Liu, Guangzhong; Wu, Guodong; Sheng, Lijian; Cao, Zhengyu; Guo, Shuyuan; Dong, Shaohong; Sun, Xin*; Tian, Ye*European Journal of Clinical Pharmacology, 2022, 78(9): 1391-1398.被引 2
  • Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
    Song, Kai; Jin, Xuan; Kim, Moo-Hyun*; Li, Jia-Xin; Jin, Cai-De; Yuan, Song-Lin; Song, Zhao-Yan; Jin, En-Ze; Lee, Kwang-Min; Lim, Kyung-Hee; Cho, Young-RakJournal of Clinical Medicine, 2022, 11(9): 2480.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Platelets
发表日期
2022-11-17
卷期
第 33 卷, 第 8 期
页码
1146-1152
DOI
10.1080/09537104.2022.2052036
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81830012]; Youth Program of the National Natural Science Foundation of China [81900374]; CS Optimizing Antithrombotic Research Fund [BJUHFCSOARF20180109]

作者

  • H

    He, Meijiao (第一作者)

    1 · harbin med univ

  • Y

    Yan, Wei

    1 · harbin med univ

查看全部 10 位作者收起作者
  • Z

    Zhang, Yun

    1 · harbin med univ

  • K

    Kong, Yihui

    1 · harbin med univ

  • H

    Han, Xuejie

    1 · harbin med univ

  • R

    Ren, Jie

    1 · harbin med univ

  • Z

    Zhao, Zhongyang

    1 · harbin med univ

  • L

    Liu, Guangzhong

    1 · harbin med univ

  • S

    Shi, Jing (通讯)

    1 · harbin med univ

  • L

    Li, Yue (通讯)

    1 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417